{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"55","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Time (in months) patients who achieved a complete response using the RECIST criteria were alive on study","dispersionType":"Full Range","groups":[{"description":"azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.\n\nlenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.","id":"OG000","title":"Lenalidomide and Azacitidine"}],"paramType":"MEDIAN","populationDescription":"Only patients with complete response","reportingStatus":"POSTED","timeFrame":"After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months","title":"Overall Survival Among Patients With Complete Response","type":"SECONDARY","unitOfMeasure":"months"}